Evidence map›Paper›PMID 37480464›Full record

ReviewAdvances in neurobiology2023

Co-administration of Nanowired Oxiracetam and Neprilysin with Monoclonal Antibodies to Amyloid Beta Peptide and p-Tau Thwarted Exacerbation of Brain Pathology in Concussive Head Injury at Hot Environment.

Ala Nozari, Aruna Sharma, Zhenguo Wang, Lianyuan Feng, Dafin F Muresanu, Z Ryan Tian, José Vicente Lafuente, Anca D Buzoianu, Lars Wiklund, Hari Shanker Sharma

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in neurobiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
6.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 5 countries.

Ala NozariAnesthesiology & Intensive Care, Chobanian & Avedisian School of Medicine, Boston University, Boston, MA, USA.
Aruna SharmaInternational Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
Zhenguo WangShijiazhuang Pharma Group NBP Pharmaceutical Co., Ltd., Shijiazhuang, Hebei Province, China.
Lianyuan FengDepartment of Neurology, Bethune International Peace Hospital, Zhongshan, Hebei Province, China.
Dafin F MuresanuDepartment of Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania.
Z Ryan TianDepartment of Chemistry & Biochemistry, University of Arkansas, Fayetteville, AR, USA.
José Vicente LafuenteLaNCE, Department of Neuroscience, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain.
Anca D BuzoianuDepartment of Clinical Pharmacology and Toxicology, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Lars WiklundInternational Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
Hari Shanker SharmaInternational Experimental Central Nervous System Injury & Repair (IECNSIR), Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden.
Uppsala University Hospital · SEBethune International Peace Hospital · CNBoston University · USIuliu Hațieganu University of Medicine and Pharmacy · ROShijiazhuang Yiling Pharmaceutical (China) · CNUniversity of Agricultural Sciences and Veterinary Medicine of Cluj-Napoca · ROUniversity of Arkansas at Fayetteville · USUniversity of the Basque Country · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Environmental temperature adversely affects the outcome of concussive head injury (CHI)-induced brain pathology. Studies from our laboratory showed that animals reared at either cold environment or at hot environment exacerbate brain pathology following CHI. Our previous experiments showed that nanowired delivery of oxiracetam significantly attenuated CHI-induced brain pathology and associated neurovascular changes. Military personnel are the most susceptible to CHI caused by explosion, blasts, missile or blunt head trauma leading to lifetime functional and cognitive impairments affecting the quality of life. Severe CHI leads to instant death and/or lifetime paralysis. Military personnel engaged in combat operations are often subjected to extreme high or low environmental temperature zones across the globe. Thus, further exploration of novel therapeutic agents at cold or hot ambient temperatures following CHI are the need of the hour. CHI is also a major risk factor for developing Alzheimer's disease by enhancing amyloid beta peptide deposits in the brain. In this review, effect of hot environment on CHI-induced brain pathology is discussed. In addition, whether nanodelivery of oxiracetam together with neprilysin and monoclonal antibodies (mAb) to amyloid beta peptide and p-tau could lead to superior neuroprotection in CHI is explored. Our results show that co-administration of oxiracetam with neprilysin and mAb to AβP and p-tau significantly induced superior neuroprotection following CHI in hot environment, not reported earlier.

Indexed as

Antibodies, MonoclonalBrain Injuries, TraumaticNeprilysinPyrrolidinesAmyloid beta-PeptidesAnimalsBrainHot TemperatureHumansNanowiresNeuroprotectiontau ProteinsAmyloid beta-PeptidesAntibodies, MonoclonalNeprilysinoxiracetamPyrrolidinestau ProteinsBlood–brain barrierBrain edemabrain pathologyConcussive head injuryHot environmentNanowired deliveryNeuroprotectionOxiracetam

Identifiers

PMID37480464
OpenAlexW4385143223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.